Brendan J Kelly
Brendan J Kelly, MD, MS
Assistant Professor of Medicine (Infectious Diseases) at the Hospital of the University of Pennsylvania
Attending Physician, Hospital of the University of Pennsylvania
Attending Physician, Penn Presbyterian Medical Center
Director Fecal Microbiota Transplantation Program, Hospital of the University of Pennsylvania
Attending Physician, Good Shepherd Penn Partners
Senior Scholar, Center for Clinical Epidemiology and Biostatistics
Director, Antimicrobial Resistance and Healthcare Epidemiology Study collaborative (ARES) Scientific Laboratory, University of Pennsylvania
Department: Medicine
Contact information
731 Blockley Hall
Philadelphia, PA 19104
Philadelphia, PA 19104
Graduate Group Affiliations
Publications
Education:
AB (History and Science)
Harvard College, Harvard University, 2002.
MD
College of Physicians and Surgeons, Columbia University, 2007.
MSCE (Genetic Epidemiology)
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, 2013.
Permanent linkAB (History and Science)
Harvard College, Harvard University, 2002.
MD
College of Physicians and Surgeons, Columbia University, 2007.
MSCE (Genetic Epidemiology)
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, 2013.
Description of Clinical Expertise
respiratory tract infection; Clostridium difficile infection; HIVDescription of Research Expertise
microbial ecology; next-generation sequencing; respiratory tract microbiome; ventilator-associated infection; antimicrobial resistance; Clostridium difficile infectionSelected Publications
Yarbrough ML, Dumm RE, Bry L, Kelly BJ, Schwartz D, Uberoi A.: Microbiome-Based Diagnostics for Disease: Where Are We Now and Where Are We Headed? Clin Chem 70(6): 792-797, Jun 2024.Emilia C. Wilkins, Laura L. Cowden, Anne Jaskowiak-Barr, Lauren Dutcher, Brendan J. Kelly: Stability of gut microbial community composition among donors to a clinical fecal microbiota transplant program. American Society for Microbiology (ASM) Microbe 2024 (Atlanta, GA, United States). 14(1): 155, June 2024.
Matthew J. Ziegler, Leigh Cressman, Anne Jaskowiak-Barr, Pam Tolomeo, Brendan J. Kelly: Post-antibiotic risk for recurrent lower respiratory tract infection during prolonged hospitalisation. European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2024 (Barcelona, Spain). April 2024.
Tanneti NS, Patel AK, Tan LH, Marques AD, Perera RAPM, Sherrill-Mix S, Kelly BJ, Renner DM, Collman RG, Rodino K, Lee C, Bushman FD, Cohen NA, Weiss SR.: Comparison of SARS-CoV-2 variants of concern in primary human nasal cultures demonstrates Delta as most cytopathic and Omicron as fastest replicating. mBio 15(3): e0312923, Apr 2024.
Marques AD, Graham-Wooten J, Fitzgerald AS, Sobel Leonard A, Cook EJ, Everett JK, Rodino KG, Moncla LH, Kelly BJ, Collman RG, Bushman FD.: SARS-CoV-2 evolution during prolonged infection in immunocompromised patients. mBio 15(5): e0011024, Mar 2024.
Kelly BJ, Kwon JH, Woodworth MH.: Escape Velocity - The Launch of Microbiome Therapies. J Infect Dis 230(1): 2-4, Mar 2024.
Ziegler MJ, Anesi J, Tolomeo P, Glaser L, Cowden C, Cressman L, Huang E, Patel A, Lautenbach E, Kelly BJ: Screening and targeted prophylaxis for Clostridioides difficile infection: STOP-CDI. Infectious Diseases Society of America, IDWeek. Oral Presentation; 2024 Oct; Los Angeles, CA. 2024.
Ziegler MJ, Anesi J, Tolomeo P, Glaser L, Cowden L, Cressman L, Huang E, Patel A, Lautenbach E, Kelly BJ: Screening and Targeted Prophylaxis for Clostridioides difficile Infection: STOP-CDI. Submitted and under review. 2024.
Wilkins EC, Loughrey S, Patel A, Anesi J, Kelly BJ: Metagenomic Profiling Reveals Post-Kidney Transplant Urinary Microbiome Change. Submitted and under review. 2024.
Andy UU, Wilson NG, Bittinger K, Kreines FM, Arya LA, Kelly BJ: Impact of Fecal Microbiota Transplantation on Recipients with High Baseline Gut Bacterial Community Diversity: a Pilot Trial. Submitted and under review. 2024.